Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00728442
First received: July 31, 2008
Last updated: September 2, 2013
Last verified: September 2013

July 31, 2008
September 2, 2013
December 2008
April 2010   (final data collection date for primary outcome measure)
Compliance of multidisciplinary staff meeting (MSM) decisions with OncoDoc2 guideline-based recommendations at one year : MSM decisions are recorded on a weekly basis. [ Time Frame: Every week ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00728442 on ClinicalTrials.gov Archive Site
  • Compliance of actually administered treatments with OncoDoc2 recommendations at 18 months (treatments administration may last until 8 months after the therapeutic decision has been taken by MSMs) [ Time Frame: at 18 months ] [ Designated as safety issue: No ]
  • typology of non-compliant reasons for both MSM decisions and treatments administration [ Time Frame: at 18 months ] [ Designated as safety issue: No ]
  • patient profiles associated with non-guideline-compliant therapeutic decisions. [ Time Frame: at 18 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer
Impact of the OncoDoc2 Decision Support System on Compliance of Multidisciplinary Staff Meeting Decisions With Clinical Practice Guidelines in the Management of Non-metastatic Breast Cancer.

The objective of the study is to evaluate how the use of OncoDoc2, a computerized guideline-based decision support system, could improve the compliance of multidisciplinary staff meeting decisions with local clinical practice guidelines in the management of non-metastatic breast cancer.

In France, to promote the quality of cancer care, decisions have currently to be made according to clinical practice guidelines (CPGs) during regularly organized multidisciplinary staff meetings (MSMs). Dissemination of textual CPGs has a poor impact on clinical practice as opposed to the use of clinical decision support systems (CDSSs) known to improve compliance with CPGs. OncoDoc2 is a CDSS providing patient-specific recommendations based on CPGs for non-metastatic female breast cancer management elaborated by the CancerEst INTERMEDICAL collaboration.The main goal of the study is to evaluate the effect of the routine use of OncoDoc2 during MSMs on compliance of MSM decisions with local CPGs. Impact will be measured by the compliance rate of MSM decisions with OncoDoc2 recommendations. The design of the study relies on a cluster randomized controlled trial. Under the assumption of a baseline compliance rate of 70% without intervention, an expected compliance rate of 90% in the intervention group (α = 5%, β = 20%), an inter-cluster variability of 5%, and 59 decisions per center, the required number of centers is 3 in each group, or 177 decisions in each arm. The study will be conducted in cancer care centers (public and private) from Paris area, France.This prospective trial will be conducted in two steps. First, baseline compliance rates will be measured in each center. Then, the 6 centers will be randomized into 2 arms. In the intervention arm, OncoDoc2 will be used during MSMs at decision time. Every case of non-adherence with system recommendations will have to be justified by clinicians. In both arms and after each MSM, MSM decisions will be recorded as well as patient characteristics and OncoDoc2 will be used for each patient case to get system recommendations. In the intervention arm, OncoDoc2 recommendations obtained by MSM will also be recorded, as well as the reason for non following recommendations in case MSM decision does not comply with guidelines.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Breast Cancer
Device: ONCODOC LOGICIEL
Introduction of a computer-based decision support system in the medical decision process
Other Name: ONCODOC LOGICIEL
  • Experimental: 1
    medical decision based on computerized guideline-based decision support system
    Intervention: Device: ONCODOC LOGICIEL
  • No Intervention: 2
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
816
April 2011
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Non metastatic, including invasive and in situ, breast cancers as well as axillary cancer without breast tumor.
  • At least one therapeutic MSM decision.

Exclusion Criteria:

  • Breast disease without cancer
  • Metastatic breast cancer
  • Male breast cancer
  • Breast cancer cases when medical records are not accessible to investigators
  • Management but not therapeutic breast cancer decisions (diagnostic investigations, treatment follow-up, delayed decisions…)
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00728442
K 070603
No
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Serge UZAN, MD, PhD Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP